Author

Jiuzhou Wang

Observed name: Wang, Jiuzhou

Observed institutions: St John of God Subiaco Hospital, University of Minnesota, Memorial Sloan Kettering Cancer Center, North Carolina State University, University of International Business and Economics, University of Minnesota System, Bon Secours Hospital Cork, Ghent University Hospital, Agostino Gemelli University Polyclinic, Southern University of Science and Technology, ImmunoGen (United States), Sarah Cannon, Institut Català d'Oncologia, Dana-Farber Cancer Institute, Essen University Hospital, Royal Marsden Hospital, Vall d'Hebron Hospital Universitari, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Kliniken Essen-Mitte, The US Oncology Network, Hospital Universitari Germans Trias i Pujol, Astellas Pharma (United States), Vall d'Hebron Institute of Oncology, Weill Cornell Medical Center, European Institute of Oncology, University of Milano-Bicocca, University of California, Davis, KU Leuven

ORCID: 0000-0003-0703-7255

Observed ORCID: 0000-0003-0703-7255

OpenAlex ID: A5033190268

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

2015 · Karen Kelly, Nasser K. Altorki, et al. · Journal of Clinical Oncology · 480

PDF

Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study

2023 · Ursula A. Matulonis, Domenica Lorusso, et al. · Journal of Clinical Oncology · 395

PDF

A Skew-symmetric Representation of Multivariate Distributions

2002 · Jiuzhou Wang, Joseph Boyer, et al. · NCSU Libraries Repository (North Carolina State University Libraries) · 131

PDF

Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

2023 · Lucy Gilbert, Ana Oaknin, et al. · Gynecologic Oncology · 121

The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring

2020 · Gaohong Dong, Lu Mao, et al. · Journal of Biopharmaceutical Statistics · 89

The Win Ratio: On Interpretation and Handling of Ties

2019 · Gaohong Dong, David C. Hoaglin, et al. · Statistics in Biopharmaceutical Research · 71

A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results.

2014 · Karen Kelly, Nasser K. Altorki, et al. · Journal of Clinical Oncology · 44

Adjusting win statistics for dependent censoring

2020 · Gaohong Dong, Bo Huang, et al. · Pharmaceutical Statistics · 33

Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study

2016 · Regina I. Jakacki, Margaret A. Foley, et al. · Journal of Neuro-Oncology · 30

A note on an equivalence between chi-square and generalized skew-normal distributions

2003 · Jiuzhou Wang, Joseph Boyer, et al. · Statistics & Probability Letters · 27

Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: Final analysis.

2021 · David M. O'Malley, Ana Oaknin, et al. · Journal of Clinical Oncology · 24

Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the SORAYA Study (LBA 4)

2022 · Ursula Matulonis, Domenica Lorusso, et al. · Gynecologic Oncology · 21

Adjuvant erlotinib (E) versus placebo (P) in non-small cell lung cancer (NSCLC) patients (pts) with tumors carrying EGFR-sensitizing mutations from the RADIANT trial.

2014 · Frances A. Shepherd, Nasser K. Altorki, et al. · Journal of Clinical Oncology · 21

Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Characterization of antitumor activity in the SORAYA study.

2022 · Ursula A. Matulonis, Ana Oaknin, et al. · Journal of Clinical Oncology · 19

PDF

A phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies.

2020 · Naval Guastad Daver, Pau Montesinos, et al. · Journal of Clinical Oncology · 13

Deep IDA: a deep learning approach for integrative discriminant analysis of multi-omics data with feature ranking—an application to COVID-19

2024 · Jiuzhou Wang, Sandra E Safo · Bioinformatics Advances · 11

PDF

MIRASOL (GOG 3045/ENGOT OV-55): A randomized, open-label, phase III study of mirvetuximab soravtansine versus investigator’s choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression.

2020 · Kathleen N. Moore, Toon Van Gorp, et al. · Journal of Clinical Oncology · 10

A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

2019 · Naval G. Daver, Harry P. Erba, et al. · Blood · 10

Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study

2023 · Ursula A. Matulonis, Domenica Lorusso, et al. · Obstetrical & Gynecological Survey · 9

18/#499 Mirvetuximab soravtansine and carboplatin for treatment of patients with recurrent folate receptor alpha-positive platinum-sensitive ovarian cancer: a final analysis

2022 · Kathleen Moore, David O’Malley, et al. · International Journal of Gynecological Cancer · 9

PDF

Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer.

2020 · Lucy Gilbert, Ana Oaknin, et al. · Journal of Clinical Oncology · 8

Comparative analysis of cellular expression pattern of schizophrenia risk genes in human versus mouse cortex

2019 · Hai-Long Zhang, Jia-Wen Long, et al. · Cell & Bioscience · 8

PDF

A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

2021 · Naveen Pemmaraju, Giovanni Marconi, et al. · Blood · 6

A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

2021 · Naval Daver, Ahmed Aribi, et al. · Blood · 6

MIRASOL: A randomized, open-label, phase 3 study of mirvetuximab soravtansine vs. investigator’s choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression (297)

2022 · Kathleen Moore, Gottfried Konecny, et al. · Gynecologic Oncology · 5

Works count: 50

Citation count: 1,629

H-index: 14

I10-index: 18